文献速递糖尿病垂体与肾上腺疾病

艾司西酞普兰改善低出生体重男性的高皮质醇血症和胰岛素抵抗并伴边缘脑结构改变

Escitalopram Ameliorates Hypercortisolemia and Insulin Resistance in Low Birth Weight Men With Limbic Brain Alterations.
PubMed 文献 · J Clin Endocrinol Metab · 2018-01-01

研究比较40例低出生体重(LBW)男性与20例匹配正常出生体重(NBW)男性的胰岛素作用、LHPA轴功能和边缘脑结构,随后将LBW受试者随机双盲接受艾司西酞普兰20 mg/d或安慰剂治疗3个月。LBW男性相比NBW男性胰岛素敏感性降低、游离皮质醇升高,艾司西酞普兰使游离皮质醇正常化并改善亚极量胰岛素敏感性。

要点

  • LBW男性相比NBW男性Rdsubmax和Rdmax分别低约16%和约12%,24小时游离皮质醇高约20%。
  • LBW男性凌晨5点游离皮质醇升高约99%,且与左侧丘脑和腹内侧前额叶皮层结构改变相关。
  • LBW男性接受艾司西酞普兰20 mg/d治疗3个月后游离皮质醇正常化,Rdsubmax较安慰剂改善约24%。

核心结论

  • LBW相比NBW男性显示调节LHPA轴的关键脑结构改变、游离皮质醇升高和胰岛素抵抗,艾司西酞普兰改善这些缺陷,提示LHPA轴调节化合物可能改善LBW受试者的胰岛素作用。

研究设计与样本

  • 第一部分比较40例年轻健康LBW男性和20例匹配NBW男性的胰岛素作用、LHPA轴功能和边缘脑结构。
  • 采用两阶段高胰岛素正葡萄糖钳夹、24小时激素血浆谱和磁共振成像检查。
  • 第二部分将全部LBW受试者随机双盲接受艾司西酞普兰20 mg/d或安慰剂治疗3个月,随后完全复查。

主要发现

  • LBW相比NBW男性Rdsubmax低约16%(P=0.01),Rdmax低约12%(P=0.01)。
  • LBW相比NBW男性24小时游离皮质醇水平高约20%(P=0.02),主要由凌晨5点升高约99%驱动(P<0.001)。
  • 这些变化与左侧丘脑和腹内侧前额叶皮层结构改变相关。
  • LBW男性中,艾司西酞普兰相比安慰剂使游离皮质醇水平正常化,并使Rdsubmax改善约24%(P=0.04)。

关键数值与推荐

  • 主要结局指标(第二部分):Rdmax/Rdsubmax和血浆游离皮质醇24小时曲线下面积的变化。

临床怎么用

  • 作者认为艾司西酞普兰改善LBW男性的高皮质醇血症和胰岛素抵抗,提示LHPA轴调节化合物可能改善LBW受试者的胰岛素作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Low birth weight (LBW; <2500 g) is linked to the development of insulin resistance and limbic-hypothalamic-pituitary-adrenal (LHPA) axis hyperactivity. OBJECTIVE: Our first aim was to study insulin action, LHPA axis function, and limbic brain structures in young, healthy LBW men vs normal birthweight (NBW) controls (part 1). Our second aim was to investigate the effects of escitalopram vs placebo in LBW men in the LHPA axis and insulin sensitivity (part 2). DESIGN SETTING, PARTICIPANTS, AND INTERVENTION: The maximal (Rdmax) and submaximal (Rdsubmax) rates of insulin-stimulated glucose turnover, LHPA axis, and brain morphology were examined in 40 LBW men and 20 matched NBW men using two-stage hyperinsulinemic euglycemic clamp, 24-hour hormone plasma profiles, and magnetic resonance imaging. Subsequently, all LBW subjects underwent randomized and double-blind treatment with escitalopram 20 mg/d or placebo for 3 months followed by a complete reexamination. MAIN OUTCOME MEASURES (PART 2): Changes in Rdmax/Rdsubmax and plasma-free cortisol 24-hour area under the curve. RESULTS: In LBW vs NBW, Rdsubmax and Rdmax were ∼16% (P = 0.01) and ∼12% (P = 0.01) lower, respectively, and 24-hour free cortisol levels were ∼20% higher (P = 0.02), primarily driven by a ∼99% increase at 05:00 am (P < 0.001). Furthermore, these changes were related to structural alterations within left thalamus and ventromedial prefrontal cortex. However, in LBW men, exposure to escitalopram normalized the free cortisol levels and improved the Rdsubmax by ∼24% (P = 0.04) compared with placebo. CONCLUSIONS: LBW vs NBW displayed alterations in key brain structures modulating the LHPA axis, elevated free cortisol levels, and insulin resistance. Escitalopram administration ameliorated these defects, suggesting a potential for LHPA axis modulation compounds to improve insulin action in LBW subjects.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Buhl CS, Stødkilde-Jørgensen H, Videbech P, et al. Escitalopram Ameliorates Hypercortisolemia and Insulin Resistance in Low Birth Weight Men With Limbic Brain Alterations. J Clin Endocrinol Metab. 2018. PMID: 29053851. doi:10.1210/jc.2017-01438

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。